Global Cardiovascular Genetic Testing Market Size Study, by Disease, by Technology, by Testing Type, by Application and Regional Forecasts 2022-2032

Description

Global Cardiovascular Genetic Testing Market is valued at approximately USD 9.07 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 11.2% over the forecast period 2024-2032. Cardiovascular genetic testing is an increasingly vital tool for assessing an individual's genetic risk for a spectrum of cardiovascular diseases, including coronary artery disease, hypertension, cardiomyopathies, and other related disorders. Given the rapidly growing prevalence of cardiovascular conditions globally, early detection through genetic testing facilitates the implementation of targeted preventive measures, thereby reducing the morbidity and mortality associated with these diseases.

The rising incidence of cardiovascular diseases, particularly coronary artery disease (CAD), is a significant driver propelling the growth of the cardiovascular genetic testing market. With an estimated 18.6 million deaths attributed to cardiovascular diseases each year, the demand for early detection methods is intensifying. According to the World Health Organization (WHO), cardiovascular disease remains the leading cause of death worldwide, claiming approximately 17.9 million lives annually. Furthermore, projections indicate that by 2030, this number could exceed 23 million, underscoring the critical need for advanced diagnostic tools like genetic testing in cardiovascular care. Additionally, the growing adoption of minimally invasive techniques, including catheter-based interventions and robot-assisted surgeries, is enhancing the scope of cardiovascular care applications. These advancements offer numerous advantages such as faster recovery times, reduced complication risks, and shorter hospital stays, thereby boosting the demand for cardiovascular genetic testing.

The global market is also benefiting from increased wellness and preventive health initiatives. As preventive healthcare gains traction, there is a growing interest among individuals to understand their hereditary risk factors for cardiovascular diseases. Public health campaigns and educational initiatives are raising awareness about the importance of proactive healthcare, which is driving the demand for genetic testing. However, the market faces challenges, including the complexities of data management and interpretation, and the ethical and privacy concerns associated with the handling of sensitive genetic information. These factors could potentially hinder the market's growth.

The global cardiovascular genetic testing market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Rest of the World. North America dominates the market, with the U.S. leading the region due to a large patient population and strong demand for innovative therapies. Favorable reimbursement policies and the presence of key market players further bolster the market in this region. Meanwhile, the Asia-Pacific region is expected to witness significant growth due to rising awareness about cardiovascular diseases, expanding healthcare infrastructure, and increasing prevalence in densely populated countries like China and India. The region's market is also driven by the growing number of retail pharmacies and improving access to healthcare services.

Major market players included in this report are:

Bio-Rad Laboratories Inc. (U.S.)
Danaher
Thermo Fisher Scientific, Inc.
Daan Gene Co., Ltd.
F. Hoffmann-La Roche, Ltd.
Genentech, Inc.
Genomictree, Inc.
HTG Molecular Diagnostics, Inc.
Illumina, Inc.
Integragen
Laboratory Corporation of America Holdings
Luminex Corporation
Molecular MD Corp.
Myriad Genetics, Inc.
Natera, Inc.

The detailed segments and sub-segment of the market are explained below:

By Disease:

Inherited Cardiomyopathies
Hypertrophic Cardiomyopathy (HCM)
Dilated Cardiomyopathy (DCM)
Arrhythmia
Aortopathies
Others

By Technology:

Cytogenetic Testing
Biochemical Testing
Molecular Testing

By Testing Type:

Predictive Testing
Carrier Testing
Prenatal and Newborn Testing
Diagnostic Testing
Pharmacogenomic Testing
Others

By Application:

Chromosome Analysis
Genetic Disease Diagnosis
Cardiovascular Disease Diagnosis
Others
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Cardiovascular Genetic Testing Market Executive Summary

1.1. Global Cardiovascular Genetic Testing Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Disease
- 1.3.2. By Technology
- 1.3.3. By Testing Type
- 1.3.4. By Application
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Cardiovascular Genetic Testing Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Cardiovascular Genetic Testing Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Incidence of Cardiovascular Diseases
- 3.1.2. Increasing Utilization of Minimally Invasive Techniques
3.2. Market Challenges
- 3.2.1. Data Management and Interpretation
- 3.2.2. Patient and Provider Acceptance
3.3. Market Opportunities
- 3.3.1. Improved Healthcare Access and Affordability
- 3.3.2. Wellness and Preventive Health Initiatives

Chapter 4. Global Cardiovascular Genetic Testing Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Cardiovascular Genetic Testing Market Size & Forecasts by Disease (2022-2032)

5.1. Segment Dashboard
5.2. Global Cardiovascular Genetic Testing Market: Disease Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Inherited Cardiomyopathies
- 5.2.2. Hypertrophic Cardiomyopathy (HCM)
- 5.2.3. Dilated Cardiomyopathy (DCM)
- 5.2.4. Arrhythmia
- 5.2.5. Aortopathies
- 5.2.6. Others

Chapter 6. Global Cardiovascular Genetic Testing Market Size & Forecasts by Technology (2022-2032)

6.1. Segment Dashboard
6.2. Global Cardiovascular Genetic Testing Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Cytogenetic Testing
- 6.2.2. Biochemical Testing
- 6.2.3. Molecular Testing

Chapter 7. Global Cardiovascular Genetic Testing Market Size & Forecasts by Testing Type (2022-2032)

7.1. Segment Dashboard
7.2. Global Cardiovascular Genetic Testing Market: Testing Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Predictive Testing
- 7.2.2. Carrier Testing
- 7.2.3. Prenatal and Newborn Testing
- 7.2.4. Diagnostic Testing
- 7.2.5. Pharmacogenomic Testing
- 7.2.6. Others

Chapter 8. Global Cardiovascular Genetic Testing Market Size & Forecasts by Application (2022-2032)

8.1. Segment Dashboard
8.2. Global Cardiovascular Genetic Testing Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Chromosome Analysis
- 8.2.2. Genetic Disease Diagnosis
- 8.2.3. Cardiovascular Disease Diagnosis
- 8.2.4. Others

Chapter 9. Global Cardiovascular Genetic Testing Market Size & Forecasts by Region (2022-2032)

9.1. North America Cardiovascular Genetic Testing Market
- 9.1.1. U.S. Cardiovascular Genetic Testing Market
  - 9.1.1.1. Disease Breakdown Size & Forecasts, 2022-2032
  - 9.1.1.2. Technology Breakdown Size & Forecasts, 2022-2032
  - 9.1.1.3. Testing Type Breakdown Size & Forecasts, 2022-2032
  - 9.1.1.4. Application Breakdown Size & Forecasts, 2022-2032
- 9.1.2. Canada Cardiovascular Genetic Testing Market
9.2. Europe Cardiovascular Genetic Testing Market
- 9.2.1. U.K. Cardiovascular Genetic Testing Market
- 9.2.2. Germany Cardiovascular Genetic Testing Market
- 9.2.3. France Cardiovascular Genetic Testing Market
- 9.2.4. Spain Cardiovascular Genetic Testing Market
- 9.2.5. Italy Cardiovascular Genetic Testing Market
- 9.2.6. Rest of Europe Cardiovascular Genetic Testing Market
9.3. Asia-Pacific Cardiovascular Genetic Testing Market
- 9.3.1. China Cardiovascular Genetic Testing Market
- 9.3.2. India Cardiovascular Genetic Testing Market
- 9.3.3. Japan Cardiovascular Genetic Testing Market
- 9.3.4. Australia Cardiovascular Genetic Testing Market
- 9.3.5. South Korea Cardiovascular Genetic Testing Market
- 9.3.6. Rest of Asia Pacific Cardiovascular Genetic Testing Market
9.4. Latin America Cardiovascular Genetic Testing Market
- 9.4.1. Brazil Cardiovascular Genetic Testing Market
- 9.4.2. Mexico Cardiovascular Genetic Testing Market
- 9.4.3. Rest of Latin America Cardiovascular Genetic Testing Market
9.5. Middle East & Africa Cardiovascular Genetic Testing Market
- 9.5.1. Saudi Arabia Cardiovascular Genetic Testing Market
- 9.5.2. South Africa Cardiovascular Genetic Testing Market
- 9.5.3. Rest of Middle East & Africa Cardiovascular Genetic Testing Market

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. Bio-Rad Laboratories Inc.
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. Danaher
- 10.3.3. Thermo Fisher Scientific, Inc.
- 10.3.4. Daan Gene Co., Ltd.
- 10.3.5. F. Hoffmann-La Roche, Ltd.
- 10.3.6. Genentech, Inc.
- 10.3.7. Genomictree, Inc.
- 10.3.8. HTG Molecular Diagnostics, Inc.
- 10.3.9. Illumina, Inc.
- 10.3.10. Integragen
- 10.3.11. Laboratory Corporation of America Holdings
- 10.3.12. Luminex Corporation
- 10.3.13. Molecular MD Corp.
- 10.3.14. Myriad Genetics, Inc.
- 10.3.15. Natera, Inc.

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes